rss

Author index

April 1998, Volume 51, Issue 2

[Table of contents]
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Amineva, K K

    • AgNORs in the myocardium in ischaemic heart disease complicated by heart failure: a postmortem study. Mol Path 1998;51:102-104 doi:10.1136/mp.51.2.102

  2. Aplan, P D

    • Pseudo-rearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukaemia patients. Mol Path 1998;51:85-89 doi:10.1136/mp.51.2.85

  3. Ascoli, V

    • Absence of HHV-8 DNA sequences in malignant mesothelioma. Mol Path 1998;51:113-114 doi:10.1136/mp.51.2.113

  4. Ashburn, D

    • Improved diagnosis of reactivated toxoplasmosis. Mol Path 1998;51:105-109 doi:10.1136/mp.51.2.105

B

  1. Baffa, R

    • p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Path 1998;51:80-84 doi:10.1136/mp.51.2.80

  2. Barlow, A L

    • Demystified ... FISH. Mol Path 1998;51:62-70 doi:10.1136/mp.51.2.62

  3. Bell, S M

    • Evidence for a common mutation in hereditary pancreatitis. Mol Path 1998;51:115-117 doi:10.1136/mp.51.2.115

  4. Bennett, C

    • Evidence for a common mutation in hereditary pancreatitis. Mol Path 1998;51:115-117 doi:10.1136/mp.51.2.115

  5. Borzio, F

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

  6. Borzio, M

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

  7. Brecher, M L

    • Pseudo-rearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukaemia patients. Mol Path 1998;51:85-89 doi:10.1136/mp.51.2.85

  8. Bruno, S

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

  9. Busatto, G

    • p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Path 1998;51:80-84 doi:10.1136/mp.51.2.80

C

  1. Carnovale Scalzo, C

    • Absence of HHV-8 DNA sequences in malignant mesothelioma. Mol Path 1998;51:113-114 doi:10.1136/mp.51.2.113

  2. Casson, A G

    • p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Path 1998;51:71-79 doi:10.1136/mp.51.2.71

  3. Colloredo, G

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

D

  1. Davidson, M M

    • Improved diagnosis of reactivated toxoplasmosis. Mol Path 1998;51:105-109 doi:10.1136/mp.51.2.105

  2. Deane, R

    • PCNA and Ki-67 labelling indices in pre-irradiated and post-irradiated astrocytomas: a comparative immunohistochemical analysis for evaluation of proliferative activity. Mol Path 1998;51:90-95 doi:10.1136/mp.51.2.90

  3. Derenzini, M

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

  4. Doshi, R

    • PCNA and Ki-67 labelling indices in pre-irradiated and post-irradiated astrocytomas: a comparative immunohistochemical analysis for evaluation of proliferative activity. Mol Path 1998;51:90-95 doi:10.1136/mp.51.2.90

  5. Dower, S K

    • Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Path 1998;51:55-61 doi:10.1136/mp.51.2.55

E

  1. Eskandarian, S

    • p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Path 1998;51:71-79 doi:10.1136/mp.51.2.71

F

  1. Ferrari, A R

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

G

  1. Gould, C P

    • Demystified ... FISH. Mol Path 1998;51:62-70 doi:10.1136/mp.51.2.62

  2. Gudkova, A Y

    • AgNORs in the myocardium in ischaemic heart disease complicated by heart failure: a postmortem study. Mol Path 1998;51:102-104 doi:10.1136/mp.51.2.102

H

  1. Ho-Yen, D O

    • Improved diagnosis of reactivated toxoplasmosis. Mol Path 1998;51:105-109 doi:10.1136/mp.51.2.105

J

  1. Joss, A W

    • Improved diagnosis of reactivated toxoplasmosis. Mol Path 1998;51:105-109 doi:10.1136/mp.51.2.105

L

  1. Leandro, G

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

  2. Lench, N J

    • Evidence for a common mutation in hereditary pancreatitis. Mol Path 1998;51:115-117 doi:10.1136/mp.51.2.115

  3. Lewis, C E

    • Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Path 1998;51:55-61 doi:10.1136/mp.51.2.55

  4. Lo Coco, F

    • Absence of HHV-8 DNA sequences in malignant mesothelioma. Mol Path 1998;51:113-114 doi:10.1136/mp.51.2.113

M

  1. Mamaev, N N

    • AgNORs in the myocardium in ischaemic heart disease complicated by heart failure: a postmortem study. Mol Path 1998;51:102-104 doi:10.1136/mp.51.2.102

  2. Markham, A F

    • Evidence for a common mutation in hereditary pancreatitis. Mol Path 1998;51:115-117 doi:10.1136/mp.51.2.115

  3. McLaughlin, J

    • p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Path 1998;51:71-79 doi:10.1136/mp.51.2.71

N

  1. Nardi, F

    • Absence of HHV-8 DNA sequences in malignant mesothelioma. Mol Path 1998;51:113-114 doi:10.1136/mp.51.2.113

O

  1. Oliveri, F

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

  2. Ozcelik, H

    • p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Path 1998;51:71-79 doi:10.1136/mp.51.2.71

P

  1. Parenti, A R

    • p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Path 1998;51:80-84 doi:10.1136/mp.51.2.80

  2. Pennington, T H

    • Improved diagnosis of reactivated toxoplasmosis. Mol Path 1998;51:105-109 doi:10.1136/mp.51.2.105

  3. Pierce, E

    • PCNA and Ki-67 labelling indices in pre-irradiated and post-irradiated astrocytomas: a comparative immunohistochemical analysis for evaluation of proliferative activity. Mol Path 1998;51:90-95 doi:10.1136/mp.51.2.90

  4. Pistilli, A

    • Absence of HHV-8 DNA sequences in malignant mesothelioma. Mol Path 1998;51:113-114 doi:10.1136/mp.51.2.113

  5. Plebani, M

    • p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Path 1998;51:80-84 doi:10.1136/mp.51.2.80

Q

  1. Qwarnstrom, E E

    • Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Path 1998;51:55-61 doi:10.1136/mp.51.2.55

R

  1. Redston, M

    • p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Path 1998;51:71-79 doi:10.1136/mp.51.2.71

  2. Roncalli, M

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

  3. Royds, J A

    • Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Path 1998;51:55-61 doi:10.1136/mp.51.2.55

  4. Rugge, M

    • p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Path 1998;51:80-84 doi:10.1136/mp.51.2.80

  5. Ruol, A

    • p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Path 1998;51:80-84 doi:10.1136/mp.51.2.80

S

  1. Schünemann, H J

    • Pseudo-rearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukaemia patients. Mol Path 1998;51:85-89 doi:10.1136/mp.51.2.85

  2. Shiao, Y H

    • p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Path 1998;51:80-84 doi:10.1136/mp.51.2.80

  3. Signoretti, S

    • Absence of HHV-8 DNA sequences in malignant mesothelioma. Mol Path 1998;51:113-114 doi:10.1136/mp.51.2.113

  4. Stanulla, M

    • Pseudo-rearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukaemia patients. Mol Path 1998;51:85-89 doi:10.1136/mp.51.2.85

  5. Sun, L B

    • A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay. Mol Path 1998;51:110-112 doi:10.1136/mp.51.2.110

T

  1. Tammemagi, M

    • p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Path 1998;51:71-79 doi:10.1136/mp.51.2.71

  2. Thandla, S

    • Pseudo-rearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukaemia patients. Mol Path 1998;51:85-89 doi:10.1136/mp.51.2.85

  3. Trerè, D

    • Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Path 1998;51:96-101 doi:10.1136/mp.51.2.96

W

  1. Waters, J J

    • Demystified ... FISH. Mol Path 1998;51:62-70 doi:10.1136/mp.51.2.62

  2. Wen, J M

    • A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay. Mol Path 1998;51:110-112 doi:10.1136/mp.51.2.110

Z

  1. Zhang, M

    • A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay. Mol Path 1998;51:110-112 doi:10.1136/mp.51.2.110

  2. Zheng, M H

    • A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay. Mol Path 1998;51:110-112 doi:10.1136/mp.51.2.110

    • Pathology jobs

    Pathology jobs

    Show me all >>